Mabwell 9MW1911 Anti-ST2 Monoclonal Antibody Reduces COPD Moderate-to-Severe Exacerbations by 81% at 900 mg in Phase 1b/2a Trial; Phase 3 Expected End of 2026 (ERS Congress Coverage)
Mabwell Biosciences presented at the European Respiratory Society Congress 2026 in Barcelona (September 5-9, 2026) — with syndicated press coverage continuing through Saturday September 12 — Phase 1b/2a results for 9MW1911, an anti-ST2 monoclonal antibody developed on Mabwell's B-lymphocyte screening platform in China. In the 9MW1911-C03 study of former smokers with moderate-to-severe COPD, the annualized rate of moderate-to-severe exacerbations was reduced by 81% at the 900 mg dose and 24% at the 600 mg dose versus placebo; annualized severe exacerbation rate reductions were 100% and 47% respectively. The Phase 3 trial is expected to initiate around end of 2026 in China; the FDA has cleared the IND application for a Phase 2a U.S. trial. 9MW1911 targets ST2 (the IL-33 receptor) — the same biological pathway targeted by Regeneron/Sanofi's itepekimab and GSK's depemokimab in COPD. Sanofi and Regeneron's Phase 3 AERIFY-1 and AERIFY-2 itepekimab trials in COPD had mixed results reported May 2025; Mabwell's data support continued ST2 blockade testing in the disease.